Erdafitinib Alternatives Compared
| Erdafitinib | Pembrolizumab | Cisplatin |
|
|---|
| Erdafitinib | Pembrolizumab | Cisplatin |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Bladder Cancer, Urothelial Carcinoma. Erdafitinib may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Breast Cancer, Bladder Cancer, Cervical Cancer, Biliary Tract Tumor, Colorectal Cancer, Endometrial Cancer, Esophageal Carcinoma, Gastric Cancer, Head and Neck Cancer, Hepatocellular... View more |
Prescription only
Prescribed for Bladder Cancer, Anal Cancer, Blood Cell Transplantation, Bone Marrow Transplantation, Brain Tumor, Cervical Cancer, Nasopharyngeal Carcinoma, Neuroblastoma, Non Small Cell Lung Cancer... View more |
Related suggestions Bladder Cancer
|
|||||||
| More about Erdafitinib | More about Pembrolizumab | More about Cisplatin | ||||||||
| Ratings & Reviews | ||||||||||
|
Erdafitinib has an average rating of 10.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Pembrolizumab has an average rating of 5.0 out of 10 from a total of 262 ratings on Drugs.com. 42% of reviewers reported a positive effect, while 48% reported a negative effect. |
Cisplatin has an average rating of 9.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
| Drug Class | ||||||||||
| Side Effects | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
Lower cost generic |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Cisplatin prices |
||||||||
| Dosage Forms Available | ||||||||||
|
N/A |
N/A |
|
||||||||
| Brand Names | ||||||||||
| Balversa | Keytruda |
N/A |
||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
|
59 hours |
624 hours |
73 hours |
||||||||
| CSA Schedule ** View glossary of terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 232 drugs are known to interact with Erdafitinib:
|
A total of 402 drugs are known to interact with Pembrolizumab:
|
A total of 446 drugs are known to interact with Cisplatin:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
April 12, 2019 |
N/A |
December 19, 1978 |
||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
|
||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.